[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339667-105":59,"doc-detail-339667-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","clinical-breast-exam-contribution-to-breast-cancer-diagnosis-in-brca-mutation-carriers-vs-average-to-intermediate-risk-women","Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women","","Purpose evaluates whether clinical breast exam (CBE) adds meaningful diagnostic value for breast cancer beyond regular screening mammography in high-risk women. A retrospective comparison contrasts BRCA mutation carriers receiving regular breast cancer surveillance with average to intermediate risk women undergoing routine screening, both using CBE during scheduled visits. Women with histologically confirmed breast cancer are included, and CBE yield is assessed as the percentage of cancers detected by CBE alone. Results quantify detection rates and the number of CBEs needed per diagnosis.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/clinical-breast-exam-contribution-to-breast-cancer-diagnosis-in-brca-mutation-carriers-vs-average-to-intermediate-risk-women/339667/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/clinical-breast-exam-contribution-to-breast-cancer-diagnosis-in-brca-mutation-carriers-vs-average-to-intermediate-risk-women/339667.png","ImageObject",300,407,{"name":92,"@type":93},"Noah","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the purpose of the study regarding CBE and breast cancer diagnosis?","Question",{"text":112,"@type":113},"To evaluate the contribution of clinical breast exam (CBE) to breast cancer diagnosis in high-risk women, comparing BRCA mutation carriers to average to intermediate risk women undergoing regular screening.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the study conducted and who were included?",{"text":117,"@type":113},"A retrospective chart review included consecutive screening visits for BRCA mutation carriers and average to intermediate risk women, with women with histologically confirmed breast cancer included.",{"name":119,"@type":110,"acceptedAnswer":120},"What did the results show about the diagnostic contribution of CBE?",{"text":121,"@type":113},"CBE contributed to breast cancer diagnosis in 2% of BRCA mutation carriers and 4% of non-carriers, with over 4,000 CBEs needed to diagnose one cancer; in BRCA carriers, cancers were palpated during surveillance rounds not including MRI.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339667,1790896978,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":39,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":46,"preview_page_count":19,"preview_urls":144},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Breast Cancer Research and Treatment (2024) 207:111–118  \n[https://doi.org/10.1007/s10549-024-07345-3](https://doi.org/10.1007/s10549-024-07345-3)  \nClinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women  \nTehillah S. Menes1,4 · Douglas Zippel1,4 · Miri Sklair‑Levy2,3,4 · Eitan Friedman2,4 · Rinat Bernstein‑Molho2,4 · Renata Faermann2,3 · Dana Madorsky Feldman2  \nReceived: 26 November 2023 / Accepted: 10 April 2024 / Published online: 26 May 2024 © The Author(s) 2024  \nAbstract  \nPurpose The contribution of clinical breast exam (CBE) to breast cancer diagnosis in average risk women undergoing regular screening mammography is minimal. To evaluate the role of CBE in high-risk women, we compared BC diagnosis by CBE in BRCA mutation carriers undergoing regular BC surveillance to average to intermediate risk women undergoing regular breast cancer screening.  \nMethods A retrospective chart review of all consecutive screening visits of BRCA mutation carriers (January 2012–October 2022) and average to intermediate risk women (November 2016–December 2022) was completed. Women with histologically confirmed BC diagnosis were included. Additional CBE yield for BC diagnosis, defined as the percentage of all BC cases detected by CBE alone, was assessed in both groups.  \nResults Overall, 12,997 CBEs were performed in 1,328 BRCA mutation carriers in whom 134 BCs were diagnosed. In 7,949 average to intermediate risk women who underwent 15,518 CBEs, 87 BCs were diagnosed. CBE contributed to BC diagnosis in 3 (2%) BRCA mutation carriers and 3 (4%) non-carriers. In both groups, over 4,000 CBEs were needed in order to diagnose one cancer. In all 3 BRCA mutation carriers BC was palpated during the surveillance round that did not include MRI. In the average to intermediate risk group, 2 of 3 cancers diagnosed following CBE findings were in a different location from the palpable finding.  \nConclusions The contribution of CBE to BC diagnosis is marginal for all women including BRCA mutation carriers. In BRCA mutation carriers, CBE appears redundant during the MRI surveillance round.  \nKeywords Breast cancer · Clinical breast exam · BRCA · Surveillance  \nIntroduction  \nWith improvements in breast imaging, the role of clinical breast exam (CBE) in screening average risk women is increasingly being questioned; with a recent report suggesting a very low yield in women undergoing regular  \n* Tehillah S. Menes [Tehillah.menes@sheba.health.gov.il](Tehillah.menes@sheba.health.gov.il)  \n1 Department of Surgery, Sheba Medical Center, Ramat Gan, Israel  \n2 Meirav Center for Women’s Health and High-Risk Clinic, Sheba Medical Center, Ramat Gan, Israel  \n3 Division of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel  \n4 Tel Aviv School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel  \nmammography screening [1] . The American Cancer Society (ACS) does not recommend CBE for BC screening in average risk women at any age [2] . This recommendation is based on lack of level 1 evidence of any proven benefit for CBE either as a stand-alone tool or in conjunction with screening mammography [3] . The National Cancer Comprehensive Network [4] recommends a clinical encounter starting at age 25, which includes a CBE in asymptomatic individuals. Despite lack of proof of efficacy of CBE in average risk women, it may play a role in high-risk women, specifically BRCA mutation carriers. Inclusion of CBE in high-risk surveillance protocols varies worldwide, with some societies recommending annual or bi-annual CBE, while others do not [5, 6] . The ESMO recent recommendations [7] for surveillance of BRCA mutation carriers clearly state that “Clinical breast examination is of no value as a screening tool”, referencing a report by Hettipathirana et al [8] . In their report,  \n35 cancers were diagnosed in 414 BRCA mutation carriers between 2001 and 2019. Of these, two BCs were detected ","cbCaisLGLUa1aVO5","https://ap.wps.com/l/cbCaisLGLUa1aVO5","pdf",1713159,"English","# Abstract\n## Purpose\n## Methods\n## Results\n## Conclusions\n# Introduction\n# Methods\n## Study population","[{\"question\":\"What was the purpose of the study regarding CBE and breast cancer diagnosis?\",\"answer\":\"To evaluate the contribution of clinical breast exam (CBE) to breast cancer diagnosis in high-risk women, comparing BRCA mutation carriers to average to intermediate risk women undergoing regular screening.\"},{\"question\":\"How was the study conducted and who were included?\",\"answer\":\"A retrospective chart review included consecutive screening visits for BRCA mutation carriers and average to intermediate risk women, with women with histologically confirmed breast cancer included.\"},{\"question\":\"What did the results show about the diagnostic contribution of CBE?\",\"answer\":\"CBE contributed to breast cancer diagnosis in 2% of BRCA mutation carriers and 4% of non-carriers, with over 4,000 CBEs needed to diagnose one cancer; in BRCA carriers, cancers were palpated during surveillance rounds not including MRI.\"}]","Clinical breast exam contribution to breast cancer diagnosis in BRCA mutation carriers vs. average to intermediate risk women | PDF",1790031529,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c01d6794bc3af3a0e91807b65809de92.webp",983,1305,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c2308fa3f1a55fb7a474bb84c9c1e4d.webp",982,1304,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3997b9ff13a04be94936c64ba4dd057a.webp",981,1303,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d9af7656c579e39be4144294b1a98163.webp",980,1301]